• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

    Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

  2. Merck shares slip as blood cancer drug study enrollment paused

    Merck shares slip as blood cancer drug study enrollment paused

  3. New Monotherapy Data for Merck ’s KEYTRUDA® (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting

    New Monotherapy Data for Merck ’s KEYTRUDA® (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting

  4. Longer Term Follow-Up Data with Merck ’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be ...

    Longer Term Follow-Up Data with Merck ’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting

  5. With More than One-Year Follow-Up, Merck ’s KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients ...

    With More than One-Year Follow-Up, Merck ’s KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure

  6. New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck ’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer

    New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck ’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer

  7. New Data Show Durability of Response for Merck ’s KEYTRUDA® (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor ...

    New Data Show Durability of Response for Merck ’s KEYTRUDA® (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type

  8. Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck ’s KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small ...

    Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck ’s KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1

12345

©2017 Morningstar Advisor. All right reserved.